MDNA 113
Alternative Names: MDNA-113Latest Information Update: 11 Sep 2024
At a glance
- Originator Medicenna Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Sep 2024 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumours released by Medicenna Therapeutics
- 09 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours released by Medicenna Therapeutics
- 03 Nov 2023 Pharmacodynamics data from preclinical study in Solid tumours released by Medicenna Therapeutics